Press Release: Sanofi completes acquisition of DR-0201

Press Release: Sanofi completes acquisition of DR-0201

Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. The acquisition bolsters Sanofi's ambition to become the foremost immunology company and broadens the company's leading immunology pipeline. DR-0201, now named SAR448501, has shown robust B-cell depletion in …

C4X Discovery bags milestone for IL-17A blocker from Sanofi - European Biotechnology Magazine

C4X Discovery Holdings Ltd has received a €8m milestone payment from the French pharmaceutical company Sanofi for its preclinical IL-17A inhibitor. This payment is based on a licence agreement from 2021, under which the British company could receive up to €414m, including royalties. The post C4X Discovery bags milestone for IL-17A blocker from Sanofi appeared first on European Biotechnology Magazine.